Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904–12.
Article CAS PubMed Google Scholar
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242–7.
Article CAS PubMed Google Scholar
Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol. 2007;78:21–8.
Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, et al. Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biol Blood Marrow Transpl. 2016;22:226–31.
Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006;37:719–24.
Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transpl. 2007;40:437–41.
Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1890–900.
Article CAS PubMed Google Scholar
Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–12.
Article CAS PubMed Google Scholar
Aladağ KarakulakE, Demiroğlu H, Büyükaşik Y, Turgut M, Aksu S, Sayinalp N, et al. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk J Med Sci. 2020;50:1851–6.
Partanen A, Turunen A, Silvennoinen R, Valtola J, Pyörälä M, Siitonen T, et al. Impact of the number of cryopreserved CD34(+) cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: experience from the GOA study. J Clin Apher. 2023;38:33–44.
Lebel E, Lajkosz K, Masih-Khan E, Reece D, Trudel S, Tiedemann R, et al. The impact of CD34(+) cell collection yields for autologous transplant on survival outcomes in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:850–6.
Article CAS PubMed Google Scholar
Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647–652.
Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transpl Cell Ther. 2023;29:567–71.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.
Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862.
Article CAS PubMed Google Scholar
Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–8.
Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15:199–236.
Jantunen E, Turunen A, Varmavuo V, Partanen A. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion. 2024;64:742–50.
Article CAS PubMed Google Scholar
Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–9.
Article CAS PubMed Google Scholar
Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.
Article CAS PubMed Google Scholar
Raschle J, Ratschiller D, Mans S, Mueller BU, Pabst T. High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer. 2011;105:970–4.
Article CAS PubMed Google Scholar
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transpl. 2015;50:673–8.
Kakihana K, Ohashi K, Akiyama H, Sakamaki H. Correlation between survival and number of mobilized CD34+ cells in patients with multiple myeloma or Waldenström macroglobulinemia. Pathol Oncol Res. 2010;16:583–7.
Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214–8.
Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol. 2009;135:637–42.
Article CAS PubMed Google Scholar
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023;13:68.
Lee SE, Lim JY, Kim TW, Ryu DB, Park SS, Jeon YW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. J Immunother Cancer. 2019;7:35.
Lim JY, Kim TW, Ryu DB, Park SS, Lee SE, Kim BS, et al. Myeloma-secreted galectin-1 potently interacts with CD304 on monocytic myeloid-derived suppressor cells. Cancer Immunol Res. 2021;9:503–13.
Article CAS PubMed Google Scholar
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023;13:112.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.
Article CAS PubMed Google Scholar
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.
Article CAS PubMed Google Scholar
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.
Article CAS PubMed Google Scholar
Lemonakis K, Tatting L, Lisak M, Carlson
留言 (0)